Clinical Characteristics of Posttransplant Lymphoproliferative Disorder After Cord Blood Transplantation Without Antithymocyte Globulin

• Published in: Clinical lymphoma, myeloma and leukemia Vol. 22; no. 7; pp. 495 - 503
• Main Authors: Sumi, Masahiko, Satomi, Hidetoshi, Kitahara, Mari, Kazumoto, Hiroko, Shishido, Tsutomu, Kaiume, Hiroko, Sato, Keijiro, Ueki, Toshimitsu, Hiroshima, Yuki, Ito, Ichiro, Kobayashi, Hikaru
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.07.2022
• Subjects: Epstein–Barr virus; Graft-versus-host disease; mycophenolate mofetil; Posttransplant lymphoproliferative disorder; Rituximab; DLBCL; haplo-SCT; GVHD; PTCL-NOS; CBT; Posttransplant lymphoproliferative disorder; allo-SCT; EBV; PTLD; TBI; HSCT; Epstein–Barr virus; Graft-versus-host disease; IM; EBMT; OS; CI; MMF; Rituximab; PSL; EBER; RIC; MAC; CsA; ATG; CuI; Tac; SOT; mycophenolate mofetil; PCR; MALT
• ISSN: 2152-2650; 2152-2669; 2152-2669
• DOI: 10.1016/j.clml.2021.12.015

CBT with ATG use is a well-known PTLD risk factor. However, little is known regarding the clinical features of PTLD after ATG-free CBT. We analyzed the incidence, risk factors and prognosis of PTLD in 183 adults undergoing ATG-free CBT. Fifteen patients (diffuse large B-cell lymphoma, n = 9, mucosa-...